To include your compound in the COVID-19 Resource Center, submit it here.

LY2127399: Phase III started

Eli Lilly disclosed in its 4Q10 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE